Figure 2. Association of Canakinumab and Placebo With Incident Major Adverse Cardiovascular Events (MACE) According to TET2 Clonal Hematopoiesis of Indeterminate Potential (CHIP) Status.

Kaplan-Meier curves are displayed for the rate of MACE in placebo and canakinumab-treated patients (50-, 150-, and 300-mg doses combined) without CHIP (A), patients with CHIP (B), TET2 patients with CHIP (C), or non-TET2 patients with CHIP (D). A Cox proportional hazard model was used to calculate hazard ratios with covariates of age, time to last myocardial infarction, and baseline log₂(high-sensitivity C-reactive protein).